Stacey Melquist

7.5k total citations · 2 hit papers
31 papers, 1.3k citations indexed

About

Stacey Melquist is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Stacey Melquist has authored 31 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cardiology and Cardiovascular Medicine, 11 papers in Surgery and 9 papers in Molecular Biology. Recurrent topics in Stacey Melquist's work include Lipid metabolism and disorders (12 papers), Cancer, Lipids, and Metabolism (9 papers) and Lipoproteins and Cardiovascular Health (7 papers). Stacey Melquist is often cited by papers focused on Lipid metabolism and disorders (12 papers), Cancer, Lipids, and Metabolism (9 papers) and Lipoproteins and Cardiovascular Health (7 papers). Stacey Melquist collaborates with scholars based in United States, Canada and Australia. Stacey Melquist's co-authors include Judith Bender, Ashley Cannon, Michael Hutton, Linda R. White, Jan Aasly, Sigrid Botne Sando, Olav Sletvold, Stian Lydersen, Ingvild Saltvedt and Peter Clifton and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Medicine.

In The Last Decade

Stacey Melquist

29 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

2022 167 citations Stacey Melquist, Jennifer Hellawell et al. Nature Medicine profile →
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia

2024 103 citations Christie M. Ballantyne, Szilárd Vasas et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stacey Melquist United States	17	438	337	289	280	194	31	1.3k
Christine Bétard Canada	21	445 1.0×	253 0.8×	96 0.3×	239 0.9×	141 0.7×	22	1.1k
Chih‐Chieh Yu Taiwan	23	636 1.5×	127 0.4×	699 2.4×	172 0.6×	102 0.5×	64	1.4k
Luisa Torres United States	16	484 1.1×	146 0.4×	54 0.2×	182 0.7×	124 0.6×	26	1.2k
G. Stoltenburg Germany	17	411 0.9×	57 0.2×	181 0.6×	75 0.3×	84 0.4×	44	1.0k
Chika Nishio Japan	17	305 0.7×	275 0.8×	401 1.4×	153 0.5×	100 0.5×	21	1.1k
Karen E. Cosgrove United Kingdom	22	647 1.5×	729 2.2×	83 0.3×	73 0.3×	987 5.1×	44	1.7k
Andreas Steege Germany	19	436 1.0×	84 0.2×	256 0.9×	337 1.2×	81 0.4×	38	1.0k
Mariko Sumi Japan	14	459 1.0×	263 0.8×	135 0.5×	145 0.5×	66 0.3×	35	928
Sung‐Sen Yang Taiwan	19	1.1k 2.4×	136 0.4×	75 0.3×	72 0.3×	226 1.2×	41	1.3k
Paul Thornhill United Kingdom	8	560 1.3×	84 0.2×	183 0.6×	311 1.1×	187 1.0×	8	1.5k

Countries citing papers authored by Stacey Melquist

Since Specialization

Citations

This map shows the geographic impact of Stacey Melquist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacey Melquist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacey Melquist more than expected).

Fields of papers citing papers by Stacey Melquist

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacey Melquist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacey Melquist. The network helps show where Stacey Melquist may publish in the future.

Co-authorship network of co-authors of Stacey Melquist

This figure shows the co-authorship network connecting the top 25 collaborators of Stacey Melquist. A scholar is included among the top collaborators of Stacey Melquist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stacey Melquist. Stacey Melquist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ballantyne, Christie M., Daniel Gaudet, Robert S. Rosenson, et al.. (2025). Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia. Journal of the American College of Cardiology. 85(19). 1839–1854. 4 indexed citations

Vasas, Szilárd, Masoud Azizad, Peter Clifton, et al.. (2024). †Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results. Journal of clinical lipidology. 18(4). e560–e560.

Páll, Dénes, Gerald F. Watts, Stephen C. Nicholls, et al.. (2024). †Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results. Journal of clinical lipidology. 18(4). e564–e564. 1 indexed citations

Ballantyne, Christie M., Szilárd Vasas, Masoud Azizad, et al.. (2024). Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. New England Journal of Medicine. 391(10). 899–912. 103 indexed citations breakdown →

Ballantyne, Christie M., Gerald F. Watts, Robert S. Rosenson, et al.. (2024). Abstract 4139852: Plozasiran and Triglyceride Levels in Hypertriglyceridemia: Long-Term Efficacy and Safety Data From Subjects in an Open-Label Extension Trial. Circulation. 150(Suppl_1).

Watts, Gerald F., Christian Schwabe, Russell L. Scott, et al.. (2023). RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nature Medicine. 29(9). 2216–2223. 65 indexed citations

Clifton, Peter, David Sullivan, John E. Baker, et al.. (2020). Abstract 12594: Pharmacodynamic Effect of ARO-APOC3, an Investigational Hepatocyte-targeted RNA Interference Therapeutic Targeting Apolipoprotein C3, in Patients With Hypertriglyceridemia and Multifactorial Chylomicronemia. Circulation. 142(Suppl_3). 14 indexed citations

Watts, Gerald F., Christian Schwabe, Russell Scott, et al.. (2020). Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients With Hypercholesterolemia. Circulation. 142(Suppl_3). 34 indexed citations

Watts, Gerald F., Christian Schwabe, Russell Scott, et al.. (2019). RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects. UWA Profiles and Research Repository (University of Western Australia). 140(25). 15 indexed citations

10.

Melquist, Stacey, Darren H. Wakefield, Holly Hamilton, et al.. (2016). Abstract 17167: Targeting Apolipoprotein(a) With a Novel RNAi Delivery Platform as a Prophylactic Treatment to Reduce Risk of Cardiovascular Events in Individuals With Elevated Lipoprotein (a). Circulation. 7 indexed citations

11.

Narayanan, Manikandan, Jimmy Huynh, Kai Wang, et al.. (2014). Common dysregulation network in the human prefrontal cortex underlies two neurodegenerative diseases. Molecular Systems Biology. 10(7). 743–743. 138 indexed citations

12.

Sando, Sigrid Botne, Guro Berge, Jan Aasly, et al.. (2012). P3‐095: Changes in core biomarkers in cerebrospinal fluid and cognitive ability in patients with Alzheimer's disease: A two‐year longitudinal study. Alzheimer s & Dementia. 8(4S_Part_13). 1 indexed citations

13.

Sando, Sigrid Botne, Stacey Melquist, Ashley Cannon, et al.. (2008). Risk‐reducing effect of education in Alzheimer's disease. International Journal of Geriatric Psychiatry. 23(11). 1156–1162. 62 indexed citations

14.

Sando, Sigrid Botne, Stacey Melquist, Ashley Cannon, et al.. (2008). APOE ε4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central Norway. BMC Neurology. 8(1). 9–9. 194 indexed citations

15.

Golan, Maciej P., Stacey Melquist, Krzysztof Safranow, et al.. (2008). Analysis of <i>UBQLN1</i> Variants in a Polish Alzheimer’s Disease Patient: Control Series. Dementia and Geriatric Cognitive Disorders. 25(4). 366–371. 9 indexed citations

16.

Wszołek, Zbigniew K., Yasuhiko Baba, Ian R. Mackenzie, et al.. (2006). Autosomal dominant dystonia-plus with cerebral calcifications. Neurology. 67(4). 620–625. 28 indexed citations

17.

Mackenzie, Ian R., Matthew Baker, John Woulfe, et al.. (2006). A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. Brain. 129(4). 853–867. 79 indexed citations

18.

Toft, Mathias, Sigrid Botne Sando, Stacey Melquist, et al.. (2005). LRRK2 mutations are not common in Alzheimer's disease. Mechanisms of Ageing and Development. 126(11). 1201–1205. 25 indexed citations

19.

Melquist, Stacey & Judith Bender. (2004). An Internal Rearrangement in an Arabidopsis Inverted Repeat Locus Impairs DNA Methylation Triggered by the Locus. Genetics. 166(1). 437–448. 23 indexed citations

20.

Melquist, Stacey & Judith Bender. (2003). Transcription from an upstream promoter controls methylation signaling from an inverted repeat of endogenous genes inArabidopsis. Genes & Development. 17(16). 2036–2047. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact